**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 70144

**Manuscript Type:** CASE REPORT

**Diagnosis and guidance of treatment of breast cancer cutaneous metastases by multiple needle biopsy: A case report**

Li ZH *et al*. Breast cancer cutaneous metastases

Zhong-Hui Li, Fang Wang, Ping Zhang, Peng Xue, Shi-Jie Zhu

**Zhong-Hui Li, Fang Wang, Peng Xue, Shi-Jie Zhu,** Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, Beijing Province, China

**Ping Zhang,** Department of Pathology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, Beijing Province, China

**Author contributions:** Li ZH and Wang F conducted a clinical examination of the patient and drafted the manuscript; Zhang P provided the images; Xue P and Zhu SJ reviewed the literature and participated in drafting the manuscript; and all authors read and approved the final manuscript.

**Corresponding author: Fang Wang, MM, Associate Chief Physician,** Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Street, Chaoyang District, Beijing 100102, Beijing Province, China. wangfang0745@126.com

**Received:** August 13, 2021

**Revised:** September 16, 2021

**Accepted:** November 25, 2021

**Published online:** January 7, 2022

**Abstract**

BACKGROUND

Breast cancer patients have a high skin metastasis rate. However, reports on treatment of cutaneous metastases of breast cancer are scarce.

CASE SUMMARY

We report the treatment process for one breast cancer case with bone, lung, and skin metastases. The patient was a 43-year-old woman with advanced breast cancer and skin metastasis. She underwent pathological diagnosis by needle biopsy to guide the treatment. When the disease progressed, a new pathological diagnosis was determined by needle biopsy to guide the treatment. The patient received chemotherapy, endocrine therapy, and photodynamic dynamic therapy, followed by sonodynamic therapy.

CONCLUSION

Repeated puncture should be performed for advanced breast cancer with skin metastasis, in order to obtain the pathology and directly determine diagnosis when the disease progresses. The treatment should focus on controlling the systemic metastasis, rather than the local disease.

**Key Words:** Breast cancer; Cutaneous metastases; Needle biopsy; Exemestane and everolimus; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Li ZH, Wang F, Zhang P, Xue P, Zhu SJ. Diagnosis and guidance of treatment of breast cancer cutaneous metastases by multiple needle biopsy: A case report. *World J Clin Cases* 2022; 10(1): 345-352

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i1/345.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i1.345

**Core Tip:** Breast cancer as the most prevalent neoplasm among female individuals, is also the main source of cutaneous metastasis other than melanoma. Breast cancer skin metastasis presents at the terminal stage of advanced cancer, and local treatment can be used to control locally metastatic lesions. As for cases involving a huge breast mass with ulceration or local lesion, radiation therapy is a useful tool for symptomatic control. Advanced breast cancer with skin metastasis can be repeatedly punctured to obtain pathology to directly inform diagnosis when the disease progresses.

**INTRODUCTION**

There were more than two million newly diagnosed female breast cancer cases in 2018. Furthermore, breast cancer alone is expected to account for 25% of all new cancers in women[1]. Cutaneous metastases of primary internal malignancy are relatively uncommon, with an overall incidence of 0.7%-10.4%[2,3]. A total of 4020 patients with metastatic skin cancer, including 212 cases of skin metastasis of breast cancer, have been recorded. Breast cancer has the highest incidence of cutaneous metastasis, when compared to other solid malignancies, accounting for 51% of the total cases and 73% of the cases in women. The incidence of cutaneous metastases in patients with breast carcinoma is 30%[4]. However, the prognosis of breast cancer cutaneous metastases remains poor[5]. Furthermore, the specific treatment for cutaneous metastases of breast cancer remains un[establish](file:///C:/Users/Lenovo/AppData/Local/youdao/dict/Application/7.5.0.0/resultui/dict/?keyword=establish)ed. Therefore, we present a case diagnosed with cutaneous metastases of breast cancer, who received several different treatments through the guidance of needle biopsy, and eventually [acquire](file:///C:/Users/Lenovo/AppData/Local/youdao/dict/Application/7.5.0.0/resultui/dict/?keyword=acquire)d a relatively long survival time.

**CASE PRESENTATION**

***Chief complaints***

The patient was a 43-year-old woman who had breast cancer with lymph node, bone, and cutaneous metastases.

***History of present illness***

The patient visited Wangjing Hospital of CACMS (Beijing, China) after 5 mo of left breast pain. During this period, the patient received alternative therapy. The patient presented with a diffuse red subcutaneous rigid nodule over the left breast and chest wall (Figure 1A). In addition, the subcutaneous nodules were found to be necrotic, and the patient suffered from breathing difficulties due to malignant pleural effusion (Figure 2A).

***History of past illness***

The patient had a history of type 2 diabetes for more than half a year.

***Personal and family history***

The patient had no history of contact with an epidemic area, smoking, or drinking, and no history of familial tumor disease.

***Physical examination***

The left axillary lymph nodes were enlarged and hard, and had poor activity. The left breast shrank, and the skin tissue hardened.

***Laboratory examinations***

The serum CA15-3 concentration continued to be above the upper limit of the reference value.

***Imaging examinations***

Thoracic computed tomography (CT) showed a mass in the left breast and chest wall muscles before treatment.

**FINAL DIAGNOSIS**

The patient was diagnosed with invasive ductal carcinoma of the left breast (stage IV) in December 2015. The pathological examination of the needle biopsy sample was performed. Immunohistochemical (IHC) analysis revealed that the tumor cells were positive for estrogen receptors and progesterone receptors, and that human epidermal growth factor receptor 2 (HER2) was not amplified (Figure 3A).

**TREATMENT**

The patient received chemotherapy, which consisted of capecitabine (1500 mg/m2, twice a day on days 1-14) and docetaxel (120 mg, intravenous infusion on day one). The subcutaneous rigid nodules over the left breast and chest wall exhibited a partial response after two cycles. However, the pleural effusion increased (Figure 2B). Since the estrogen receptors and progesterone receptors were positive, the chemotherapy was changed to endocrine therapy with 25 mg of exemestane (EXE) and 10 mg of everolimus (EVE), and this commenced on April 2016. At the same time, ovarian suppression with leuprorelin was performed every 4 wk. A significant response was clinically observed after 3 mo (Figure 1B), and the cancer antigen (CA15-3) level significantly decreased (Figure 4).

The patient remained without progression for 8 mo, after which progression was noted (Figure 1C). In November 2016, progression of the metastatic skin lesions was detected (Figures 1C and 2D). Then, the serum CA15-3 concentration returned to the upper limit of the reference value. The patient received a skin punch biopsy again, and the pathology indicated triple-negative breast cancer by IHC (Figure 3B). Then, the patient received chemotherapy with adriamycin plus cyclophosphamide from December 2016 to April 2017. For the first two cycles of chemotherapy, the efficacy was evaluated as stable (Figure 2E). However, after six cycles of chemotherapy, a new red subcutaneous nodule appeared again on the left breast and chest wall skin, accompanied by stabbing pains. Hence, the patient underwent third subcutaneous nodule puncture biopsy, and the following immunostaining results were obtained: ER (10%), PR (-), HER-2 (-), and Ki-67 (90%) (Figure 3C). Although ER was positive, the ratio was low, and this could not benefit from the hormonal therapy. Hence, the patient continued to receive chemotherapy with paclitaxel liposome and carboplatin. Unfortunately, the same skin lesion progressed again after two cycles of chemotherapy. Furthermore, the metastatic lesion in the lung progressed, and the pleural effusion significantly increased. The gemcitabine chemotherapy combined with bevacizumab antiangiogenic therapy was attempted again. After one cycle of combined treatment, the skin lesion improved again, and the main signs of skin alleviation and nodule atrophy were observed. However, the patient had dyspnea due to the malignant pleural effusion. At the same time, edema began to appear on the face and neck, and the patient no longer tolerated the chemotherapy. Local treatment was chosen due to the extensive metastasis of the skin, and failure to tolerate the chemotherapy. Subsequently, the patient received photodynamic therapy (PDT) followed by sonodynamic therapy (SDT) in August 2017 (Figure 5). After 10 d, the patient’s skin lesion presented with rapid improvement (Figure 5C).

Regardless of the relief in skin lesion after the PDT and SDT treatments, the patient’s condition did not show a significant improvement.

**OUTCOME AND FOLLOW-UP**

Because the patient used large amounts of glucocorticoids during the treatment period, the patient had lung metastasis. The patient had serious lung infection, and finally died of severe pneumonia. The patient gained a 21-mo overall survival time. Comprehensive therapy and the several attempts to obtain the pathology to guide the therapy improved the overall survival and quality of life of the patient.

**DISCUSSION**

Breast cancer as the most prevalent neoplasm among female individuals, is also the main source of cutaneous metastasis other than melanoma. Generally, skin metastasis of breast cancer presents at the terminal stage of advanced cancer, but there are exceptions. For example, a recently reported case of skin metastasis of breast cancer in an old women belongs to this rare group since cutaneous metastasis was identified before the primary cancer. And the case also showed the interest of biopsy and imaging in the confirmation of the diagnosis[6]. The lesions of cutaneous metastasis can clinically present in various patterns. Inflammation and nodules are the most common presentations, while ulcerated nodules are relatively less common, which account for 10% of cases. Other rare clinical manifestations include zosteriform and lymphatic blockage, and carcinoma en cuirasse. One patient can have multiple types at the same time[7]. The lesions can be painless, or associated with pain and sensitivity, with fast initial growth and subsequent stabilization. The most common site of metastasis is the chest wall, as well as the site of the contralateral breast, the scars at the surgical incisional site, the arms, and the head and neck region[8]. For the present case, this was first detected in the chest and breast skin, and the main presentation was diffuse red rigid nodules.

The systematical analysis of patient survival after the occurrence of skin metastasis revealed that half of the patients with cutaneous metastasis die within the first 6 mo after the diagnosis, and that the median survival of patients with breast carcinoma with cutaneous metastasis is 13.8 mo[5]. Some breast cancer patients with local skin recurrence but without clinical evidence of disseminated disease, may have a good prognosis and prolonged survival[9]. However, the prognosis of advanced breast cancer patients with skin metastasis is generally poor.

There is no specific treatment for cutaneous metastases of breast cancer. For patients with advanced skin metastasis of breast cancer, systemic treatment such as chemotherapy, hormonal therapy, and anti-HER2 are main methods of therapy. The treatment of skin metastases from breast cancer mainly relies on puncture biopsy to identify the molecular type of breast cancer and then determine the specific treatment plan according to the molecular type, so puncture biopsy is indispensable for treatment.

The subtype of hormone receptor-positive breast cancer cutaneous metastases can be treated with hormonal therapy (aromatase inhibitors). For breast cancer endocrine therapy, intrinsic and acquired resistance remains a common feature that limits the success of this therapeutic strategy. The mammalian target of rapamycin (mTOR) signaling pathway plays a central role in cancer cell proliferation and resistance to endocrine therapies. Therefore, mTOR inhibitors, such as EVE, in combination with nonsteroidal aromatase inhibitors (NSAIs), might reverse the endocrine resistance and improve the clinical outcomes of patients. EVE in combination with differ­ent endocrine agents in the treatment of hormone receptor-positive breast cancer enhances the efficacy of the endocrine therapy in endocrine-naive patients, and in patients exposed to prior NSAIs. In a phase II randomized study, the use of EVE plus letrozole, when compared to placebo plus letrozole neoadjuvant therapy, for patients with estrogen receptor-positive breast cancer revealed that EVE can significantly increase the letrozole efficacy in the neoadjuvant therapy of patients with ER-positive breast cancer[10]. In the GINECO study, EVE combined with tamoxifen *vs* tamoxifen alone were used to treat patients with advanced disease pre-exposed to aromatase inhibitors, and the results suggested that tamoxifen plus EVE increased the time to progress-free survival (PFS) and overall survival, when compared to tamoxifen alone, in postmenopausal women with aromatase inhibitor-resistant metastatic breast cancer[11]. The BOLERO-2 trial revealed that EVE plus EXE is well-tolerated by patients, and provides a clinically significant PFS benefit *vs* EXE plus placebo, in the overall population of patients with hormone receptor-positive and HER-2 negative advanced breast cancer progressing during/after NSAI therapy[12]. The median PFS nearly tripled with EVE plus EXE *vs* EXE plus placebo (11.5 *vs* 4.1 mo, respectively) in patients whose disease recurred during or after the (neo)-adjuvant therapy[13]. These trials support the use of EVE combined with differ­ent endocrine agents in enhancing the efficacy of endocrine therapy for endocrine-naive patients, and for patients exposed to prior NSAIs. For the present case, EVE plus EXE was used to treat the skin metastasis of hormone receptor-positive breast cancer, and the patient received 8 mo of PFS. Therefore, EVE plus EXE for hormone receptor-positive breast cancer skin metastasis can better control the skin metastatic lesions.

In addition, local treatment can be used to control locally metastatic lesions. For cases that involve a huge breast mass with ulceration or local lesion, radiation therapy is a useful tool for symptomatic control. PDT[14,15] and SDT[16,17] have also been used to treat cutaneous metastases of breast cancer. Electrochemotherapy (ECT) is another new promising method for cutaneous metastasis, and represents a valuable skin-directed therapy for selected patients with breast cancer. A European study analyzed 125 patients with BC skin metastases who underwent ECT. It was revealed that the overall response rate at 2 mo was 90.2%, and the complete response rate was 58.4%. And in the first 48 h, 10.4% of the patients reported severe skin pain. Dermatologic toxicity included grade 3 skin ulceration (8.0%) and grade 2 skin hyperpigmentation (8.8%). The study concluded that ECT represents a valuable skin-directed therapy for breast cancers with a small tumor size, the absence of visceral metastases, HR+, and a low Ki-67 index[18]. Nevertheless, most skin lesions, with or without soft tissue infiltration, are not readily manageable by local modalities, such as surgery and/or radiation ther­apy, because skin infiltration is more likely a manifestation of systemic relapse. Therefore, thera­peutic strategies should be based on the control of the systemic disease, rather than local modalities, even for patients with skin-only lesions[9,19].

**CONCLUSION**

The present study suggests that skin metastasis of some breast cancers is an intrinsic feature, and acquired drug resistance increases the complexity of the treatment. In addition, the molecular subtypes of breast cancer may be constantly changed from the treatment process. Therefore, evaluating the immunohistochemical assay of the lesion biopsies can directly provide a diagnosis and treatment strategy. The present patient who received EVE plus EXE therapy exhibited a significant response with the resolution of the skin lesion, which lasted for over 8 mo. But after PDT and ECT treatment, the skin will experience a temporary inflammatory reaction, sometimes with erosions or ulcers and eventually crusting. Also, in the case of tumor regression, the skin may show slight hyperpigmentation. For small local skin metastasis lesions, radiotherapy, PDT, and ECT can be used to control the local lesion and provide better quality of life for patients. However, treatment strategies for cutaneous metastases of breast cancer should focus on controlling the systemic disease, rather than the local lesion, especially in patients with extensive skin infiltration.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Hu SC**, Chen GS, Wu CS, Chai CY, Chen WT, Lan CC. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. *J Am Acad Dermatol* 2009; **60**: 379-387 [PMID: 19056145 DOI: 10.1016/j.jaad.2008.10.007]

3 **Schwartz RA**. Cutaneous metastatic disease. *J Am Acad Dermatol* 1995; **33**: 161-82; quiz 183-6 [PMID: 7622642 DOI: 10.1016/0190-9622(95)90231-7]

4 **Lookingbill DP**, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. *J Am Acad Dermatol* 1993; **29**: 228-236 [PMID: 8335743 DOI: 10.1016/0190-9622(93)70173-q]

5 **Schoenlaub P**, Sarraux A, Grosshans E, Heid E, Cribier B. [Survival after cutaneous metastasis: a study of 200 cases]. *Ann Dermatol Venereol* 2001; **128**: 1310-1315 [PMID: 11908133]

6 **Sanae A**, Kaoutar I, Jamal EF, Meryem E. Cutaneous metastasis as a first sign of breast carcinoma. *Radiol Case Rep* 2021; **16**: 1899-1901 [PMID: 34113415 DOI: 10.1016/j.radcr.2021.04.064]

7 **De Giorgi V**, Grazzini M, Alfaioli B, Savarese I, Corciova SA, Guerriero G, Lotti T. Cutaneous manifestations of breast carcinoma. *Dermatol Ther* 2010; **23**: 581-589 [PMID: 21054704 DOI: 10.1111/j.1529-8019.2010.01365.x]

8 **Wong CY**, Helm MA, Kalb RE, Helm TN, Zeitouni NC. The presentation, pathology, and current management strategies of cutaneous metastasis. *N Am J Med Sci* 2013; **5**: 499-504 [PMID: 24251266 DOI: 10.4103/1947-2714.118918]

9 **Cho J**, Park Y, Lee JC, Jung WJ, Lee S. Case series of different onset of skin metastasis according to the breast cancer subtypes. *Cancer Res Treat* 2014; **46**: 194-199 [PMID: 24851112 DOI: 10.4143/crt.2014.46.2.194]

10 **Baselga J**, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. *J Clin Oncol* 2009; **27**: 2630-2637 [PMID: 19380449 DOI: 10.1200/JCO.2008.18.8391]

11 **Bachelot T**, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol* 2012; **30**: 2718-2724 [PMID: 22565002 DOI: 10.1200/JCO.2011.39.0708]

12 **Beaver JA**, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. *Future Oncol* 2012; **8**: 651-657 [PMID: 22764762 DOI: 10.2217/fon.12.49]

13 **Beck JT**, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. *Breast Cancer Res Treat* 2014; **143**: 459-467 [PMID: 24362951 DOI: 10.1007/s10549-013-2814-5]

14 **Khan SA**, Dougherty TJ, Mang TS. An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer. *Eur J Cancer* 1993; **29A**: 1686-1690 [PMID: 8398295 DOI: 10.1016/0959-8049(93)90105-o]

15 **Wen X**, Li Y, Hamblin MR. Photodynamic therapy in dermatology beyond non-melanoma cancer: An update. *Photodiagnosis Photodyn Ther* 2017; **19**: 140-152 [PMID: 28647616 DOI: 10.1016/j.pdpdt.2017.06.010]

16 **Rengeng L**, Qianyu Z, Yuehong L, Zhongzhong P, Libo L. Sonodynamic therapy, a treatment developing from photodynamic therapy. *Photodiagnosis Photodyn Ther* 2017; **19**: 159-166 [PMID: 28606724 DOI: 10.1016/j.pdpdt.2017.06.003]

17 **Pan X**, Wang H, Wang S, Sun X, Wang L, Wang W, Shen H, Liu H. Sonodynamic therapy (SDT): a novel strategy for cancer nanotheranostics. *Sci China Life Sci* 2018; **61**: 415-426 [PMID: 29666990 DOI: 10.1007/s11427-017-9262-x]

18 **Cabula C**, Campana LG, Grilz G, Galuppo S, Bussone R, De Meo L, Bonadies A, Curatolo P, De Laurentiis M, Renne M, Valpione S, Fabrizio T, Solari N, Guida M, Santoriello A, D'Aiuto M, Agresti R. Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. *Ann Surg Oncol* 2015; **22** Suppl 3: S442-S450 [PMID: 26242370 DOI: 10.1245/s10434-015-4779-6]

19 **Kong JH**, Park YH, Kim JA, Kim JH, Yun J, Sun JM, Won YW, Lee S, Kim ST, Cho EY, Ahn JS, Im YH. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations. *Oncology* 2011; **81**: 55-62 [PMID: 21934337 DOI: 10.1159/000331417]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors have no conflicts of interest to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist, and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 13, 2021

**First decision:** September 5, 2021

**Article in press:** November 25, 2021

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Alvarez-Bañuelos MT **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:** Wang JJ


**Figure Legends**




**Figure 1 Multiple nodules over the left breast and chest wall**. A: Nodules measuring 1-2 cm in size; B: Status of the skin lesions at 3 mo after endocrine therapy with 25 mg of exemestane and 10 mg of everolimus; C: After 8 mo of endocrine therapy, the metastatic skin lesions progressed.




**Figure 2 Changes in thoracic computed tomography manifestations in the patient throughout the treatment period.** A:Thoracic computed tomography showed a mass in the left breast and chest wall muscles before treatment; B: Partial response was clinically observed after two cycles of chemotherapy. However, the pleural effusion increased; C: Breast and chest wall tumors showed a significant response after 1 mo of endocrine therapy; D: The breast and chest wall tumors progressed, and the pleural effusion increased again; E: After two cycles of chemotherapy, the efficacy was evaluated as stable.



**Figure 3** **Immunohistochemical results at different puncture time points.** A:Immunohistochemical staining of the breast puncture biopsy (20 × magnification); B: High expression of ER (+), PR (+), and Ki-67 (40%), and low expression of Her-2 (-); C: Triple negative expression of ER (-), PR (-), and HER2 (-), and high expression of Ki-67 (60%); D: Low expression of ER (10%+), PR (-), HER2 (-), and high expression of Ki-67 (90%). The pathology results in A, B, and C were obtained from the same patient at different time points of puncture.



**Figure 4 Changes of the tumor marker CA15-3 in the treatment process.** The initiation of the chemotherapy (capecitabine and docetaxel) administration. The CA15-3 serum concentration continued to be above the upper limit of the reference value. After one month of therapy with EXE and EVE, the CA15-3 serum concentration immediately and sharply declined. After the second biopsy, the CA15-3 serum concentration decreased when adriamycin plus cyclophosphamide chemotherapy was administered. The trend for the tumor markers in the other treatments after the last skin lesion biopsy is shown. EXE: Exemestane; EVE: Everolimus.



**Figure 5 Skin changes before, during, and after the patient received photodynamic therapy and sonodynamic therapy.** A:Before performing photodynamic therapy (PDT) followed by sonodynamic therapy (SDT); B: At 3 d after PDT and SDT treatment for the skin lesion, the skin lesion presented with necrosis; C: The lesions had rapid improvement with necrosis, and crusting after 10 d of PDT and SDT treatment.

徽标, 公司名称

描述已自动生成

Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com

QR 代码

描述已自动生成

**© 2022 Baishideng Publishing Group Inc. All rights reserved.**